<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02584634</url>
  </required_header>
  <id_info>
    <org_study_id>B9991005</org_study_id>
    <secondary_id>2015-001879-43</secondary_id>
    <secondary_id>JAVELIN LUNG 101</secondary_id>
    <nct_id>NCT02584634</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)</brief_title>
  <official_title>A Phase 1b/2, Open-label, Dose-finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf-06463922 In Patients With Advanced Or Metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of avelumab when combined
      with either crizotinib or PF-06463922.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1b/2, open label, multi center, multiple dose, safety, pharmacokinetic and
      pharmacodynamic study of Group A and Group B in cohorts of adult patients with locally
      advanced or metastatic NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First two cycles dose limiting toxicities (DLTs) for Group A and Group B</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Confirmed Overall Response (OR) per RECIST v.1.1 for Group A</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Complete response (CR) or Partial Response (PR) from start date (first dose of study treatment) until disease progression or death.
Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control (DC)</measure>
    <time_frame>Up to 60 months.</time_frame>
    <description>DC is defined as Best Overall Response of CR, PR, or Stable Disease (SD). Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Confirmed Overall Response (Group B)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>CR or PR from start date until disease progression or death. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Time from start date to the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast</measure>
    <time_frame>Avelumab: Day 8, Crizotinib &amp; PF-06463922: 24 hours</time_frame>
    <description>Area under the plasma concentration time profile from time zero to the time of the last quantifiable concentration (Clast)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCtau</measure>
    <time_frame>Avelumab: Days 1 and 8, Crizotinib &amp; PF-06463922: Day 1</time_frame>
    <description>Area under the plasma concentration time profile after single dose from time zero to the next dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Avelumab: Day 1, Crizotinib &amp; PF-06463922: Day 1</time_frame>
    <description>Maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Avelumab: Day 1, Crizotinib &amp; PF-06463922: Day 1</time_frame>
    <description>Time for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½a</measure>
    <time_frame>Avelumab: Days 1 and 8, Crizotinib &amp; PF-06463922: Day 1</time_frame>
    <description>Terminal half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctrough</measure>
    <time_frame>Avelumab: Day 1 pre-dose sample, Crizotinib &amp; PF-06463922: Day 1</time_frame>
    <description>Predose concentration during multiple dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/Fa</measure>
    <time_frame>Avelumab: Days 1 and 8, Crizotinib &amp; PF-06463922: Day 1</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/Fa</measure>
    <time_frame>Avelumab: Days 1 and 8, Crizotinib &amp; PF-06463922: Day 1</time_frame>
    <description>Apparent volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRAUCtau</measure>
    <time_frame>Avelumab: Days 1 and 8, Crizotinib &amp; PF=06463922: Day 1</time_frame>
    <description>Metabolite to parent ratio for AUCtau</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRCmax</measure>
    <time_frame>Avelumab: Day 1, Crizotinib &amp; PF=06463922: Day 1</time_frame>
    <description>Metabolite to parent ratio for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor tissue biomarkers</measure>
    <time_frame>baseline</time_frame>
    <description>Tumor tissue biomarkers, including but not limited to, PD-L1 expression and tumor infiltrating CD8+ T cells by immunohistochemistry (IHC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>DR is defined, for patients with an objective response, as the time from first documentation of objective response (CR or PR) to the date of first documentation of objective progression of disease or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Response (TTR)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>TTR is defined, for patients with an objective response, as the time from the start date to the first documentation of objective response (CR or PR) which is subsequently confirmed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>PFS is defined as the time from start date to the date of the first documentation of PD or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALK negative Non-Small Cell Lung Cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALK positive Non-Small Cell Lung Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>MSB0010718C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06463922</intervention_name>
    <description>Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.</description>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>PF-02341066</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria

          -  Diagnosis of advanced or metastatic NSCLC. Group A must be ALK negative NSCLC and
             Group B must be ALK positive NSCLC

          -  Group A at least one prior regimen of therapy

          -  Group B any number of prior regimens.

          -  Mandatory tumor tissue available

          -  At least one measurable lesion

          -  ECOG Performance status 0 or 1

          -  Adequate bone marrow, renal, liver and pancreatic function

          -  Negative pregnancy test for females of childbearing potential

          -  Group B Phase 2: No prior systemic treatment for advanced or metastatic disease
             (adjuvant and/or neoadjuvant therapies are allowed if completed at least 6 months
             prior to study entry. No prior tyrosine kinase inhibitor therapy is allowed at any
             time prior to study entry)

        Exclusion Criteria:

          -  No prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4
             antibody.

          -  No Severe or Chronic medical conditions including gastrointestinal abnormalities or
             significant cardiac history

          -  No active infection requiring systemic therapy

          -  Prior organ transplantation including allogenic stem cell transplantation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory Investigational Drug Service</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston Inc (OCB)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aichi cancer center central hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute Hospital of JFCR</name>
      <address>
        <city>Koto-ku, Tokyo</city>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-Si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Research Pharmacy, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia de Badalona,Unidad de Farmacia Oncologica-Ensayos Clinicos</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia de Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Quiron Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08023</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B9991005&amp;StudyName=A%20Phase%201b%2F2%2C%20Open-label%2C%20Dose-finding%20Study%20To%20Evaluate%20Safety%2C%20Efficacy%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20Avelumab%20%28msb0010718c%29%20In%20Combination%20With%20Either%20Crizotinib%20Or%20Pf-06463922%20In%20Patients%20With%20Advanced%20Or%20Metastatic%20Non-small%20Cell%20Lung%20Cancer</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>ALK</keyword>
  <keyword>avelumab</keyword>
  <keyword>crizotinib</keyword>
  <keyword>PF-06463922</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

